PROCEPT BioRobotics Corp
PROCEPT BioRobotics (PRCT) faces a class action lawsuit alleging securities law violations. The suit claims the company made false statements and inflated revenue through aggressive discounting. Shareholders who bought PRCT between Feb 28, 2024, and Feb 25, 2026, may join the case by Sept 22, 2026.
Kaplan Fox & Kilsheimer LLP filed a class action lawsuit against PROCEPT BioRobotics Corporation (PRCT) on behalf of investors who bought its common stock between February 28, 2024, and February 25, 2026. The lead plaintiff deadline is September 22, 2026.
PROCEPT BioRobotics (PRCT) faces a securities class action lawsuit alleging misstatements about handpiece sales and procedure demand. Shares fell over 75% after disclosing a gap between handpiece sales and actual procedures, with unit sales contracting 30% sequentially. The case covers purchases between February 28, 2024, and February 25, 2026, with a lead plaintiff deadline of September 22, 2026.
Over the past 7 days, alphai's AI scored 2 news stories mentioning PRCT (PROCEPT BioRobotics Corp). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent PRCT coverage spans regulation, earnings and financial news.
In the last 30 days, PRCT insiders filed 1 SEC Form 4 transaction — 1 purchase ($498K) and no sales. The most active reporter was Wood Larry L, President, CEO, with 1 filing.
Potential liability and negative sentiment may pressure the stock.
Potential liability and negative sentiment could pressure the stock.
Potential settlement or judgment could drive further price volatility.
The lawsuit alleges revenue inflation via bulk-order discounts and points to prior sharp declines tied to handpiece inventory and guidance changes.
The filing is a fresh insider buy signal, but it is not a fundamental catalyst like earnings, guidance, or a deal.
alphai scores every news story that mentions PRCT with an AI model for sentiment and relevance, and aggregates insider trades from PROCEPT BioRobotics Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
PROCEPT BioRobotics (PRCT) faces a class action lawsuit alleging securities law violations. The suit claims the company made false statements and inflated revenue through aggressive discounting. Shareholders who bought PRCT between Feb 28, 2024, and Feb 25, 2026, may join the case by Sept 22, 2026.
1 min readKaplan Fox & Kilsheimer LLP filed a class action lawsuit against PROCEPT BioRobotics Corporation (PRCT) on behalf of investors who bought its common stock between February 28, 2024, and February 25, 2026. The lead plaintiff deadline is September 22, 2026.
1 min readPROCEPT BioRobotics (PRCT) faces a securities class action lawsuit alleging misstatements about handpiece sales and procedure demand. Shares fell over 75% after disclosing a gap between handpiece sales and actual procedures, with unit sales contracting 30% sequentially. The case covers purchases between February 28, 2024, and February 25, 2026, with a lead plaintiff deadline of September 22, 2026.
2 min readBleichmar Fonti & Auld LLP says a securities fraud class action has been filed against PROCEPT BioRobotics (NASDAQ:PRCT) and executives after an alleged discount program that incentivized bulk handpiece orders, potentially inflating revenue. The suit cites an 18% stock drop in Feb 2026 and earlier declines tied to Q2 2025, Q3 2025, and Q4 2025 results.
3 min readWood Larry L (President, CEO) purchased 23,900 indirectly-held shares of PROCEPT BioRobotics Corp (PRCT) at $20.85 ($0.50M total) on 2026-08-07.
2 min readProcept BioRobotics reported Q2 2026 revenue up 19% year over year to $94.5 million, citing HYDROS system demand and record ASPs, while U.S. procedures grew 21% but missed expectations due to softness in legacy AQUABEAM accounts. Full-year 2026 revenue guidance remains $390 million to $410 million; U.S. procedures guidance lowered to 54,000–56,000. Management expects positive adjusted EBITDA in Q4 2026 and ongoing HYDROS replacement cycle through 2027.
6 min readThe acquisition transforms Processa's pipeline with the addition of clinical-stage BTK inhibitor VT-7208, while a concurrent $200 million private placement is expected to fund development into 2029. Key Investor Takeaways Processa Pharmaceuticals (NASDAQ:PRCT) acquired Vidya Therapeutics, adding clinical-stage BTK inhibitor VT-7208 to its pipeline. The company simultaneously secured a private placement expected to raise approximately $200 million to fund multiple Phase 2 clinical programs.
6 min readPROCEPT BioRobotics (Nasdaq: PRCT) said it will release second-quarter 2026 financial results after market close on Aug. 4, 2026, and hold a conference call at 4:30 p.m. ET. The company noted its AQUABEAM and HYDROS robotic systems used for Aquablation therapy in urology.
1 min readPROCEPT BioRobotics (NASDAQ:PRCT) reported progress in its WATER IV prostate cancer program: enrollment completed for WATER IV RP (280 patients; Aquablation vs radical prostatectomy) with primary results expected at the AUA meeting in spring 2027, and FDA IDE approval for WATER IV AS (up to 333 patients; Aquablation vs active surveillance). Evercore ISI initiated coverage with an “Outperform” rating and $30 price target.
4 min readPROCEPT BioRobotics Corp (PRCT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. prct-20260609 0001588978 false 0001588978 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
2 min read
